Literature DB >> 29421824

The Main Determinants of Serum Resistin Level in Type 2 Diabetic Patients are Renal Function and Inflammation not Presence of Microvascular Complication, Obesity and Insulin Resistance.

Egemen Cebeci1, Cengiz Cakan2, Meltem Gursu3, Sami Uzun1, Serhat Karadag1, Macit Koldas4, Turan Calhan5, Serife Aysen Helvaci2, Savas Ozturk1.   

Abstract

AIM: The association of increased resistin levels in chronic kidney disease with diabetic nephropathy has not yet been clarified. Our aim was to analyze the relationship between serum resistin levels and various diabetic microvascular complications in patients.
METHODS: A total of 83 patients were enrolled in this cross-sectional study. The subjects were divided into 3 groups: 27 patients with type 2 diabetes mellitus (T2DM) having no diabetic retinopathy (DRP) or microalbuminuria and having normal renal function were included in Group-1, 28 patients with T2DM having DRP and normal renal function in Group-2, and 28 patients with T2DM with DRP and microalbuminuria and an estimated glomerular filtration rate (eGFR) of<60 ml/min/1.73 m2 in Group-3. Serum resistin levels were analyzed by enzyme-linked immunosorbent assay.
RESULTS: The mean age of the patients [46 female (55.4%)] was 54.8±9.1 years. The resistin level in Group-3 was significantly higher than in Group-1 and Group-2 (p<0.001).However the resistin level was not different between Group-1 (without microvascular complications) and Group-2 (with microvascular complications). The resistin level was found to be correlated negatively with eGFR (r=-0.459; p<0.001) and albumin (r=-0.402; p<0.001), and positively with high-sensitivity C-reactive protein (hs-CRP) (r=0.366; p=0.001). In multivariate analysis, it was observed that eGFR and hs-CRP were independent determinants of plasma resistin level.
CONCLUSION: The main determinants of resistin level in patients with T2DM are the level of renal function and inflammation rather than presence of microvascular complications, obesity and insulin resistance. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29421824     DOI: 10.1055/s-0043-121262

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

1.  Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers.

Authors:  Erieta Kollari; Ioanna Zografou; Christos Sampanis; Vasilios G Athyros; Triantafyllos Didangelos; Christos S Mantzoros; Asterios Karagiannis
Journal:  Hormones (Athens)       Date:  2021-10-30       Impact factor: 2.885

2.  Preserved C-peptide secretion in patients with type 1 diabetes and incipient chronic complications is associated with lower serum resistin and higher uric acid levels.

Authors:  Tomislav Bulum; Martina Tomić; Sandra Vučković-Rebrina; Vinko Roso; Marijana Vučić Lovrenčić; Lea Duvnjak
Journal:  J Diabetes Metab Disord       Date:  2020-08-29

3.  Associations between the Neutrophil-to-Lymphocyte Ratio and Diabetic Complications in Adults with Diabetes: A Cross-Sectional Study.

Authors:  Heng Wan; Yuying Wang; Sijie Fang; Yi Chen; Wen Zhang; Fangzhen Xia; Ningjian Wang; Yingli Lu
Journal:  J Diabetes Res       Date:  2020-04-28       Impact factor: 4.011

Review 4.  Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications.

Authors:  Katarzyna Zorena; Olga Jachimowicz-Duda; Daniel Ślęzak; Marlena Robakowska; Małgorzata Mrugacz
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

5.  Analysis of serum inflammatory mediators in type 2 diabetic patients and their influence on renal function.

Authors:  Liliane Silvano Araújo; Marcos Vinícius da Silva; Crislaine Aparecida da Silva; Maria de Fátima Borges; Heloísa Marcelina da Cunha Palhares; Laura Penna Rocha; Rosana Rosa Miranda Corrêa; Virmondes Rodrigues Júnior; Marlene Antônia Dos Reis; Juliana Reis Machado
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.